San Diego-based Viking Therapeutics marked by itself as a significant competitor in the weight loss drug current market in February immediately after revealing promising facts from a mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection and in March